ClinicalTrials.gg
Active, not recruitingNCT06052813Updated Feb 25, 2026

A Study of BN104 in the Treatment of Acute Leukemia

A Phase 1/2 interventional study of BN104 monotherapy and BN104 monotherapy in ALL, Adult, AML, Adult and Acute Leukaemia, sponsored by Institut de Recherches Internationales Servier (I.R.I.S.). Active, not recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Institut de Recherches Internationales Servier (I.R.I.S.) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 113 open to participants now, 125 under way, 11 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · China.

Enrollment
80th of 209
66 · median 45
Started
2023
with 13 others
Phase 1/2
33 of 232
14 open now
Primary completion
2026-12
later than 63 of 124 live
Registered
143rd of 232
by date

Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 80th largest by enrollment of the 209 interventional ones that give a count, is one of 14 that started in 2023, is one of 33 in phase 1/2, reaches primary completion later than 63 of the 124 other live ones, and was the 143rd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

113 of the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

108 more — sign in →

All 113 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.

Read the detailed description

The study is divided into 2 phases. Phase1 part will enroll 98 patients to evaluate safety and tolerance of BN104 in patients with relapsed/refractory (R/R) Acute Leukemia to determine maximum tolerated dose and recommended phase2 dose (RP2D), including approximately 66 adult patients and 32 adolescent patients with specific mutations (KMT2A gene rearrangement, NPM1 gene mutation, NUP98 mutation) enrolled at phaseI.

Phase II expansion part will enroll 168 patients and be conducted at the selected dose level to further evaluate the safety and tolerability of BN104, as well as preliminary efficacy in Acute leukemia subjects with specific mutations (KMT2A gene rearrangement or NPM1 gene mutation). Patients will be allocated into 2 Acute Leukemia subgroup cohorts depends on their genotype.

  • Cohort A: Patients with Relapsed/refractory AML subjects with NPM1 mutations
  • Cohort B: Patients with relapsed/refractory acute leukaemia with KMT2A rearrangement (including AML, ALL, or MPL)

Patients will receive orally administrated BN104 once daily or twice daily. Study drug will be administered in 28-day cycles until disease progression or unacceptable toxicity, death, Informed consent withdraw ect.

Laboratory tests will be performed weekly in Cycles 1-2, bi-weekly in Cycle3 and every 4weeks from Cycle 4 onwards. Efficacy assessment will be performed on baseline, C2D1, C3D1 and every 2 cycles from Cycle3 onwards. Additional clinical assessments and laboratory tests may be performed at discretion of the investigator as clinically indicated.

03

Conditions studied

  • ALL, Adult
  • AML, Adult
  • Acute Leukaemia
  • KMT2A Rearrangement
  • NPM1 Mutation
  • NUP98 Gene Rearrangement
  • Menin Inhibitors
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have been fully informed about the study and have voluntarily signed the ICF;
  2. Patients diagnosed with acute leukaemia (including AML, ALL, and mixed-phenotype acute leukaemia, excluding acute promyelocytic leukaemia) according to the World Health Organization (WHO) criteria in 2022, with bone marrow morphological changes (blasts/immature cells ≥ 5%), and who have been evaluated by the investigator to have no better treatment options, must meet at least one of the following conditions:

    • Primary refractory disease, newly diagnosed disease that show no response after 2 cycles of standard treatment;
    • First relapse, relapsed within 12 months after CR/CRh/CRi following consolidation/intensive therapy;
    • Relapsed after 12 months and unresponsive to conventional salvage chemotherapy;
    • Patients with 2 or more relapses;
    • Patients intolerant to intensive chemotherapy who experience disease progression during continuous low-intensity therapy; Note: Patients with secondary AML or AML transformed from MDS, MPN, can also be enrolled, but they need to meet the above criteria after the disease has transformed into AML;
  3. For all Phase I patients, the presence of NPM1 mutation, or KMT2A rearrangement, or NUP98 rearrangement must be confirmed,During Phase I, patients with other acute leukemia subtypes shown to depend on menin-KMT2A interaction (e.g., UBTF-TD) or driven by HOXA/MEIS1 overexpression may also be eligible after consultation with the Sponsor's Medical Monitor;
  4. Patients in the Phase II (single-arm pivotal clinical study) must have a confirmed NPM1 mutation or KMT2A rearrangement. Enrollment based on local testing results is acceptable with a copy of the test report provided; however, all patients are required to submit screening bone marrow samples to the central laboratory ,Eligible NPM1 mutations include exon12 type A, B, and D mutations ; other NPM1 mutations causing cytoplasmic localization require sponsor pre-approval for enrollment. KMT2A rearrangements exclude non-fusion rearrangements involving KMT2A partial tandem duplication (KMT2A-PTD).
  5. Peripheral blood white blood cell count ≤ 35 × 109/L (use of hydroxyurea to control peripheral white blood cell count is permitted);
  6. Age ≥ 12 years (for adolescent patients aged 12 years or older but not yet 18 years old, weight must be ≥ 40 kg);
  7. score 0-2;
  8. Adequate hepatic, renal, and cardiac functions
  9. Expected survival of more than 12 weeks as judged by the investigator
  10. For patients with D-dimer test results > 5 × during screening, relevant tests (such as rechecking coagulation function after a certain interval, lower extremity deep vein ultrasound, etc.) are required to exclude deep vein thrombosis, hypercoagulation, and disseminated intravascular coagulation before enrollment;
  11. Able to undergo treatment, visits, and study-related examinations as required by the protocol;
  12. Female patients of or male patients whose female partners are of childbearing potential must agree to use effective methods of during the study and for 30 days after the last dose of study drug, such as double barrier methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. women (> 45 years old and amenorrheic for more than 1 year) and surgically sterilized women are not subject to this condition.

Exclusion criteria

Exclusion Criteria:

  1. Known active central nervous system (CNS) leukaemia (including imaging abnormalities and CSF smear or flow cytometry indicating leukaemia cells; prior CNS leukaemia that has been treated and controlled is acceptable, but requires screening lumbar puncture and CSF test for confirmation, or routine standard CNS prophylaxis is acceptable);
  2. Known history of liver disease, including viral or other hepatitis or hepatic cirrhosis:

    • surface antigen (HBsAg) seropositive, requires Hepatitis B virus (HBV) DNA negative for enrollment;
    • For virus (HCV) antibody seropositive patients, HCV RNA negative result is required for enrollment.
  3. Known (HIV) infection;
  4. Pregnancy (positive pregnancy test at screening) or lactating females;
  5. Any of the following cardiac-related criteria is met:

    • Hereditary long syndrome or QTcF > 450 msec;
    • Various clinically significant cardiovascular disorders, including acute myocardial infarction, unstable angina pectoris, coronary artery bypass surgery within 6 months prior to enrollment, cardiac failure congestive of (NYHA) Class 2 or higher (including Class 2), etc.;
  6. Patient has other concomitant malignant tumours, except for:

    • Curatively treated skin basal cell carcinoma, breast cancer in situ, or cervical carcinoma in situ, etc.;
    • Patients with low-grade lymphoma who are in CR, asymptomatic, without large mass lesions, and do not require systemic therapy or radiotherapy;
    • Other malignant tumours treated with curative intent, with CR achieved for at least 2 years, and no requirement for systemic maintenance therapy or radiotherapy;
  7. Received haematopoietic stem cell transplant (ASCT) or Chimeric Antigen Receptor T-cell (CAR-T) therapy within 60 days prior to screening, or toxicity related to ASCT or CAR-T therapy has not yet resolved;
  8. Underwent allogeneic HSCT within 100 days prior to screening, or the patient still has Grade ≥ 2 acute or chronic graft versus host disease requiring systemic treatment, or the patient still requires (prednisone ≤ 10 mg/day or equivalent dose of other is permissible for screening; corticosteroids need to be gradually tapered and discontinued after enrolment unless there is a specific reason);
  9. Received donor lymphocyte infusion (DLI) within 28 days prior to screening;
  10. Prior anti-leukaemia therapy, including chemotherapy, radiotherapy, hormone therapy, targeted therapy, or immunotherapy (excluding hydroxyurea), etc., less than 2 weeks or 5 half-lives (whichever is shorter) before the start of study treatment;
  11. Previous participation in other drug clinical studies, with less than 2 weeks or 5 half-lives since the last use of a small molecule drug, or less than 4 weeks or 5 half-lives for large molecule drugs (such as antibody drugs), whichever is shorter;
  12. Previous treatment targeting menin;
  13. Toxicity from previous anti-leukaemia therapy has not recovered to Grade 0 or 1 (except for alopecia and cytopenias reasonably considered related to the underlying disease);
  14. Patients who had a chest CT scan within 1 month prior to screening showing pulmonary nodules need to undergo a T-SPOT.TB test (Tuberculosis infection T-cell spot test) during screening; those with a positive result must be excluded (no additional test required if no chest CT scan was performed within 1 month prior to screening);
  15. Uncontrolled active infection:

    • Patients with non-severe infectious complications (such as oral candida infection or uncomplicated urinary tract infection) currently receiving oral/topical anti-infective therapy may be enrolled;
    • Patients with severe infection requiring hospitalisation or intravenous antibiotic therapy within 14 days prior to enrollment, patients with no evidence of infection receiving prophylactic anti-infective, anti-fungal, or anti-viral therapy due to prolonged neutropenia may be enrolled;
    • Patients receiving intravenous antibiotic therapy or hospitalized for febrile neutropenia, but with no evidence of infectious etiology found, and whose body temperature has been normal for more than 72 hours without antipyretics, may be enrolled;
  16. Patient has known dysphagia, short-bowel syndrome, gastroparesis, or other conditions limiting oral drug intake or gastrointestinal absorption;
  17. History of severe allergy to menin inhibitors or allergy to any component of BN104;
  18. Investigator-judged insufficient compliance of the patient to participate in this clinical study;
  19. Any other disease, metabolic abnormality, physical examination abnormal, or clinically significant laboratory test abnormal that, in the investigator's judgment, gives reason to suspect that the patient has a disease or condition unsuitable for the use of the study drug, or that will affect the interpretation of the study results, or place the patient at high risk.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    200mg QD

    The starting dose cohort(200mg QD) where accelerated titrated dose-escalation method is applied, a patient will initially receive a single dose BN104 on Day 1 of Cycle 0 (3 days prior to Day 1 of Cycle 1) to evaluate the concentration of BN104 up to 72 hours after administration and the safety of single dose of BN104. Then the patient begins continuous treatment with BN104 200 mg QD on Day 1 of Cycle 1 by every 28-day treatment cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.

    Drug: BN104 monotherapy

  • Experimental
    200mg BID

    After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.

    Drug: BN104 monotherapy

  • Experimental
    400mg BID

    After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.

    Drug: BN104 monotherapy

  • Experimental
    600 BID

    After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.

    Drug: BN104 monotherapy

  • Experimental
    800 BID

    After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.

    Drug: BN104 monotherapy

  • Experimental
    Adolescent cohort - 400mg BID

    The first 3-6 patients will be dosed at 400 mg BID. If there is no significant difference in Cmax and AUC between adolescent and adult patients, and no DLT occurs in 3-6 patients or ≤1 DLT occurs in 6 patients, the dose will be escalated to 600 mg BID, and 3-6 additional adolescent patients will be enrolled. patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.

    Drug: BN104 monotherapy

  • Experimental
    Adolescent cohort - 600mg BID

    patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. If ≤1 DLT occurs in 6 patients, at 600mg bid, then enrolment will be expanded at the 600 mg BID dose level to approximately 20 patients, for patients with relapsed/refractory acute leukaemia with KMT2A rearrangement and NPM1 mutation, ensuring at least 10 patients each with KMT2A rearrangement and NPM1 mutation in relapsed/refractory acute leukaemia at the 600 mg BID dose level.

    Drug: BN104 monotherapy

  • Experimental
    Phase II CohortA - Patients with relapsed/refractory AML with NPM1 mutation

    receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)

    Drug: BN104 monotherapy - rp2d

  • Experimental
    Phase II Cohort B: r/r acute leukaemia with KMT2Ar (including AML, ALL, or MPL)

    receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)

    Drug: BN104 monotherapy - rp2d

Interventions

  • DrugZefamenibStudies of ZefamenibZefamenib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Phase I(adults): Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.

  • DrugZefamenibStudies of ZefamenibZefamenib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Phase I(adolescent): Will be administered orally twice daily (approximately every 12 hours)

  • DrugZefamenibStudies of ZefamenibZefamenib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)

06

What researchers measure

Primary outcomes

  1. PhaseI Incidence of Dose Dose limiting toxicities(DLTs)

    DLTs will be evaluated at the end of cycle 1(28 days after receiving BN104) for each dose level by evaluating abnormal laboratory examinations by the Investigator.

    Time frame: DLT last 28days(at the end of cycle 1 for each dose)

  2. PhaseI Incidence of serious adverse events(SAEs)

    SAEs will be recorded in the eCRF from time of the signing informed consent through 30 days after the last dose of BN104.

    Time frame: 36 month

  3. PhaseII efficacy assessment

    To evaluate the efficacy of BN104 in treating patients with relapsed/refractory acute leukaemia with specific mutations (KMT2A rearrangement or NPM1 mutation) by mesuring patients bone marrow blasts/immature cells(CR, CRh rate) at protocol defined efficacy assessment timepoint

    Time frame: 36 month

Secondary outcomes

  1. Phase I/II Evaluate the number and frequency of adverse events (AEs)

    Evaluate the number and frequency of adverse events (AEs) by evaluating abnormal laboratory examinations by the Investigator at each clinical visit from time of the signing informed consent through 30 days after the last dose of BN104.

    Time frame: 36 months

  2. Phase I/II Evaluate patient vital signs

    Evaluate vital signs, including body temperature, heart rate, respiration rate, and blood pressure by the Investigator at each clinical visit before taking BN104.

    Time frame: 36 months

  3. Phase I/II Evaluate electrocardiogram (ECG) assessments

    Evaluate electrocardiogram (ECG) assessments by the Investigator Prior to any examination at each clinical visit to monitor heart rate, R-R interval, QT interval and QTcF interval, QRS, and P-R interval times.

    Time frame: 36 months

  4. Phase I/II pharmacokinetic Maximum concentration (Cmax)

    To characterized Maximum Plasma Concentration \[Cmax\] of BN104 by collecting and evaluating the serum at the protocol specified time points.

    Time frame: 36 months

  5. Phase I/II pharmacokinetic Peak time(Tmax)

    To characterized Peak time(Tmax) of BN104 by collecting and evaluating the serum at the protocol specified time points

    Time frame: 36 months

  6. Phase I/II pharmacokinetic Clearance half-life (T1/2)

    To characterized Clearance half-life (T1/2) of BN104 by collecting and evaluating the serum at the protocol specified time points

    Time frame: 36 months

  7. Phase I/II pharmacokinetic Area under the blood concentration-time curve (AUC0-t)

    To characterized Area under the blood concentration-time curve (AUC0-t) of BN104 by collecting and evaluating the serum at the protocol specified time points.

    Time frame: 36 months

  8. Phase I/II pharmacokinetic metabolite M1

    To characterized BN104 major metabolite M1 by collecting and evaluating the serum at the protocol specified time points.

    Time frame: 36 months

  9. Phase I/II efficacy assessment based on Complete response (CR)

    To assess the preliminary anti-tumor activity of BN104 based on Complete response (CR) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  10. Phase I/II efficacy assessment based on Complete response with partial recovery of hematology (CRh)

    To assess the preliminary anti-tumor activity of BN104 based on Complete response with partial recovery of hematology (CRh) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  11. Phase I/II efficacy assessment based on Complete response with incomplete hematological recovery (CRi)

    To assess the preliminary anti-tumor activity of BN104 based on Complete response with incomplete hematological recovery (CRi) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  12. Phase I/II efficacy assessment Objective response rate (ORR)

    To assess the preliminary anti-tumor activity of BN104 based on Objective response rate (ORR) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  13. Phase I/II efficacy assessment based on Duration of response (DOR)

    To assess the preliminary anti-tumor activity of BN104 based on Duration of response (DOR) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  14. Phase I/II efficacy assessment based on Event-free survival (EFS)

    To assess the preliminary anti-tumor activity of BN104 based on Event-free survival (EFS) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  15. Phase I/II efficacy assessment based Relapse-free survival (RFS)

    To assess the preliminary anti-tumor activity of BN104 based Relapse-free survival (RFS) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  16. Phase I/II efficacy assessment based on Overall survival (OS)

    To assess the preliminary anti-tumor activity of BN104 based on Overall survival (OS) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  17. Phase I/II efficacy assessment Cumulative relapse rate (CIR)

    To assess the preliminary anti-tumor activity of BN104 based on Cumulative relapse rate (CIR) assessed by the Investigator at Cycle2. cycle3 and every 2 cycles thereafter through peripheral blood tests, detection of bone marrow primitive cell ratio and other morphological changes by bone marrow aspiration/biopsy

    Time frame: 36 months

  18. PhaseI pharmacokinetic biomarkers

    Changes in pharmacokinetic biomarkers (e.g., HOXA9, MEIS1, CD11b, etc.) before and after BN104 administration, and correlations with dosing and efficacy

    Time frame: 36 months

  19. correlation between specific gene alterations and clinical efficacy

    The correlation between specific gene alterations (such as NPM1 mutation, KMT2A rearrangement) and other gene alterations (such as FLT3 mutation/fusion, TP53 mutation, NUP98 fusion, etc.), and clinical efficacy.

    Time frame: 36 months

  20. Phase I/II efficacy assessment Cumulative Incidence of Death (CID)

    To assess the preliminary anti-tumor activity of BN104 based on Cumulative Incidence of Death (CID) through the time from the date of achieving remission to non-relapse death

    Time frame: 36 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 114 phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 119. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 25, 2023
StartActual
Oct 19, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06052813
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Responsible party
Sponsor
First posted
Sep 25, 2023
Start date
Oct 19, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 25, 2026

Study contacts

Depei WU, Prof.
principal investigator · The First Affiliated Hospital of Soochow University
Mingyuan Sun, Dr.
principal investigator · Institute of Hematology, Chinese Academy of Medical Sciences
Yan Li, Dr.
principal investigator · Institute of Hematology, Chinese Academy of Medical Sciences
Xudong Wei, Prof.
principal investigator · Henan Oncology Hospital
Dengju Li, Prof.
principal investigator · Tongji Hospital
Yuhua Li, Prof.
principal investigator · Southern Medical University, China
Xiaoyu Zhu, Prof.
principal investigator · Anhui Provinvcal Hospital
Fei Li, Prof.
principal investigator · The First Affiliated Hospital of Nanchang University
Jinhai Ren, Prof.
principal investigator · The Second Hospital of Hebei Medical University
He Huang, Prof.
principal investigator · Zhejiang University
Pengcheng He, Prof.
principal investigator · First Affiliated Hospital Xi'an Jiaotong University
Wei Wang, Dr.
principal investigator · The Affiliated Hospital of Qingdao University
Yu Cao, Dr.
principal investigator · The Affiliated Hospital of Qingdao University
Songfu Jiang, Prof.
principal investigator · First Affiliated Hospital of Wenzhou Medical University
Jian Ge, Prof.
principal investigator · The First Affiliated Hospital of Anhui Medical University
Bei Liu, Dr.
principal investigator · LanZhou University
Yuping Gong, Prof.
principal investigator · West China Hospital
Xiaojun Xu, Prof.
principal investigator · The Children's Hospital of Zhejiang University School of Medicine
Xiaofan Zhu, Prof.
principal investigator · Chinese Academy of Medical Sciences Haematological Diseases Hospital
Wenting Hu, Dr.
principal investigator · Shanghai Children's Medical Center
Meng LV, Dr.
principal investigator · Peking University People's Hospital
Jun Luo, Prof.
principal investigator · First Affiliated Hospital of Guangxi Medical University
Zhenfang Liu, Prof.
principal investigator · First Affiliated Hospital of Guangxi Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zefamenib

Start the discussion